Abbott Laboratories leveled up on this year’s Fortune 500 list, leaping from last year’s rank of 104 to No. 89. Why? COVID testing. Abbott was one of the first to jump into the testing market, and that alacrity has paid off; the company’s diagnostics unit, which also houses its COVID test arm, raked in more than $4 billion in sales during the first quarter of 2021 alone. Abbott, though, isn’t putting all its eggs in one basket. As life starts returning to normal, the company believes its diabetes care and glucose monitoring products will continue to fuel growth.
Lists ranking Abbott Laboratories
World’s Most Admired Companies - 2022Just as it dominates our economy, Big Tech now dom...READ MOREview in list
Latest news for Abbott Laboratories
- NewslettersBusiness leaders challenge fellow CEOs to raise their game on net-zero commitmentsMarch 31, 2022 10:04 AM UTC
- NewslettersThe pandemic has accelerated innovation across industries—particularly in health careMarch 28, 2022 9:47 AM UTC
- HealthRapid COVID tests are coming to market alongside vaccines to help America return to normalApril 1, 2021 6:45 PM UTC
- LeadershipHow Abbott, Merck, and more health care and biopharma companies took care during COVIDMarch 12, 2021 12:00 PM UTC